Clinical investigations of immunotherapy for human primary brain tumors

Zahraa I. Khamis1,2,*, Nancy Al-Akkary2,*, Timothy Hua†, Sophia A. Draughon†, Yan Li3,*, Qing-Xiang Amy Sang1,4

1Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL 32306, USA.
2Laboratory of Cancer Biology and Molecular Immunology, Department of Biochemistry, Faculty of Sciences-I, Lebanese University, Beirut 00000, Lebanon.
3Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL 32306, USA.
4Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306, USA.
*The first two authors contributed equally to this work.

Correspondence to: Prof. Qing-Xiang Amy Sang, Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL 32306, USA. E-mail: qxsang@chem.fsu.edu

How to cite this article: Khamis ZI, Al-Akkary N, Hua T, Draughon SA, Li Y, Sang QXA. Clinical investigations of immunotherapy for human primary brain tumors. Neuroimmunol Neuroinflammation 2020;7:[Online First].
http://dx.doi.org/10.20517/2347-8659.2020.43

Received: 31 May 2020  First Decision: 13 Jul 2020  Revised: 7 Aug 2020  Accepted: 31 Aug 2020  Available online: 16 Oct 2020

Academic Editor: Terry Lichtor  Copy Editor: Cai-Hong Wang  Production Editor: Jing Yu

Abstract

Human primary brain cancer is one of the most lethal and clinically challenging malignancies. The failure of conventional therapies to alleviate its poor outcome has prompted efforts to find innovative treatments. Recent breakthroughs in immunotherapy across a variety of solid tumors have set immune-based therapeutics as a pillar for brain cancer treatment. However, the unique features of brain malignancies including intratumoral heterogeneity, immunosuppressive microenvironment, and impervious blood-brain barrier, thwart the success of immunotherapeutic approaches. Yet, seminal findings regarding tumor-driven enrichment of specific immune cells granted the field novel insights to harness the immune cells to fight cancer. This review discusses the anatomical, microenvironmental, and immunobiological features of the human brain and presents an overview of immunotherapies tested for primary brain cancer patients with a special emphasis on registered phase 2, 3, and combinatorial clinical trials. Immune checkpoint inhibitors, immune cell-based therapies, cancer vaccines, oncolytic viral therapy, and combination therapies are investigated in clinical settings for the treatment of human brain tumors. Despite their occasional adverse effects, immune-targeted therapies provide a promising opportunity for primary brain cancer patients to enhance survival and improve prognosis.
INTRODUCTION

Primary brain tumors are notoriously lethal malignancies. In 2020, primary brain tumors are projected to claim the lives of 18,000 individuals in the United States alone\(^1\). With more than 220,000 global brain cancer-related deaths in 2016\(^2\), both adult and pediatric populations carry the burden of incident brain and central nervous system (CNS) cancers\(^{1,4}\). Brain malignancies can be either intracranial primary tumors arising within the brain or brain metastases most frequently derived from extracranial tumors of the lungs, breast, and skin. Primary brain tumors exhibit salient genomic, molecular, microenvironmental, and histological profiles that result in different types of brain malignancies. In adults, diffuse gliomas are the most common primary tumors of the brain and include astrocytoma, oligodendroglioma, and glioblastoma\(^5\). Medulloblastomas are the most common malignant embryonal tumors that affect childhood\(^6\). Other than categorization by cells of origin, brain tumors are assigned a “grade” reflecting growth rate. Low-grade brain tumors present a positive outlook of curable, resectable cancer with an average survival of 7 years\(^7\). Conversely, high-grade tumors are characterized by poor prognosis in light of their high heterogeneity, diffusiveness, and aggressiveness\(^{8,9}\). Low grade gliomas (astrocytomas and oligodendroglioma) are distinguished from high grade gliomas (glioblastoma) by the mutational status of two genes that encode isocitrate dehydrogenase (IDH) isozymes. IDH mutations are enriched in low grade gliomas as compared to glioblastomas and infer a strong positive prognostic marker\(^5\). The current standard-of-care therapy for gliomas consists of gross total resection followed by a standardized regimen of chemotherapy and radiotherapy. Even following such an aggressive course of treatment, patients with high-grade tumors have a 14.6-month mean survival from the time of diagnosis\(^10\), with less than 7% of patients expected to survive for 5 years\(^5\).

The distinct anatomical, immunobiological, and microenvironmental properties of the brain and its neoplasms offer significant challenges to brain cancer treatment\(^11\). Brain tumors coerce non-malignant brain components and resident immune cells (e.g., microglia) to promote their growth and help them evade antitumor immune responses\(^{12,13}\). Additionally, the impervious blood brain barrier (BBB) severely limits the efficacy and intracranial penetration of the vast majority of conventional chemotherapeutic agents\(^14\). Crossing the BBB remains a critical consideration in high-grade brain tumors\(^15\), which once resolved can allow the favorable remodeling of the tumor microenvironment (TME)\(^16\). Thus far, attempts to target conventional pathways deregulated in glioblastoma and other brain tumors have fallen short of expectations\(^17\). As a result, standard-of-care therapies remain palliative rather than curative with notable side effects, such as acute and long-term neurocognitive decline\(^{18,19}\). Therefore, researchers continue to contend with brain tumors to develop novel therapeutics that can enhance the dismal prognosis of brain cancer patients\(^20\).

Historically considered immunologically silent or immunologically privileged, recent studies have debated this concept and revealed that the human brain has afferent and efferent CNS immunity\(^21,22\). Unchallenged by the BBB, the immune system constitutes a promising opportunity to break the deadlock of brain tumor treatment. The success of immunotherapy in various solid\(^{21,24}\) and diffuse\(^25\) cancers reflects the potential of harnessing the immune system in replacing current aggressive yet ineffectual treatment protocols. This has spurred investigations to evaluate the efficacy of existing immunotherapeutic agents against primary and metastatic brain tumors\(^26-28\). The enhancement of systemic and local antitumor immune responses and the subsequent improvement in brain cancer patients’ survival is achievable with immunotherapy of relative safety and tolerability\(^{27,29,30}\). While the majority of clinical investigations in primary brain tumors remain
in their early stages, available data support the use of immunotherapy alone or in combination with other agents to achieve an intracranial response, disease remission, and improved survival\(^\text{[27,31,32]}\).

In this review, we provide a concise overview of clinical evidence from registered trials detailing immunotherapeutic approaches in the clinical management of primary brain tumors, with an emphasis on available phase 2 and 3 trials. We also discuss a compendium of available immunotherapies and their implication in the immunobiological profile of the brain TME.

**Brain tumor microenvironment**

The brain tumor microenvironment is composed of cancerous cells along with a variety of stromal cells including endothelial cells, fibroblasts, pericytes, and immune cells\(^\text{[33]}\). The tumor stroma also consists of tissue-specific resident T-cells, including astrocytes, microglia, oligodendritic cells, and neurons\(^\text{[33-36]}\), all of which are physically protected from the systemic circulation by the BBB and embedded in a modified extracellular matrix (ECM) [Figure 1]. In a normal brain, endothelial cells and pericytes interconnect with astrocytes to form the impenetrable BBB. However, neoplastic astrocytes have been shown to communicate with and support cancerous cells through the formation of the connexin43 gap junction, thus mediating the physical transfer of signaling molecules between tumor cells and astrocytes\(^\text{[37]}\). In a patient-derived glioblastoma xenograft model, active neurons promoted the proliferative activity of glioma cells via secretion of synaptic protein neuroligin-3 (NLGN3) that exerted a mitogenic signal on neoplastic cells, promoting their growth and proliferation\(^\text{[38]}\). While a wealth of evidence suggests oligodendrocyte precursors as a putative cellular origin for many forms of gliomas\(^\text{[39]}\), a recent study found that these cells provide a supportive niche for glioblastoma cells by inducing their stemness and chemo-radioresistance\(^\text{[40]}\). The majority of immune cells in the brain TME are tumor-associated macrophages (TAMs) of distinct ontogenicity, including tissue-resident microglia and recruited monocyte-derived macrophages (MDMs). Bidirectional crosstalk prevails between TAMs and cancerous cells in the brain TME. Tumor cells produce factors that recruit TAMs to the local milieu and TAMs in turn supply growth factors and cytokines that induce a protumorigenic microenvironment\(^\text{[12]}\). The ECM of the brain has a unique composition of proteins that distinguishes it from other non-CNS tissues\(^\text{[41]}\). Under the effects of cancer cells and their reprogrammed stromal cell neighbors, ECM constituents are heavily modified and promote tumor angiogenesis, progression, and immune evasion\(^\text{[13]}\). In this manner, brain tumor cells can exploitively alter and reprogram the cellular components of the stroma as well as the ECM into oncogenic drivers that mandate tumor cell proliferation and invasion.

**Immunobiology of the brain**

Translation of available immunotherapeutic approaches to brain tumors necessitates a deep understanding of the immunobiology of the brain microenvironment. The unique features of brain tumors generate an exceptionally immunosuppressive microenvironment characterized by immunoinhibitory cytokines [Figure 1]. These factors, including interleukin (IL)-6, IL-10, CCL2, TGF-β, and prostaglandin-E, are secreted by both brain cancer cells and immune cells. The complex interactions among these cells contribute to an anti-inflammatory environment\(^\text{[42]}\) that supports tumor proliferation and drug-resistance\(^\text{[43,44]}\). CCL2 chemokine recruits regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSC) to the peritumor environment\(^\text{[15,46]}\). Tregs, in turn, release the anti-inflammatory mediators IL-10 and TGF-β\(^\text{[47]}\). These two mediators potentiate immune evasion, enhance tumor growth, and contribute to poor prognosis in glioblastoma patients\(^\text{[48,49]}\). Other factors secreted by brain tumor cells include vascular endothelial growth factor (VEGF) and colony-stimulating factor-1. Both factors are implicated in hypoxia-mediated suppression of immune cells achieved through the deregulation of immune cell maturation, the skew of TAMs to a tumor-supportive M2 phenotype, and the recruitment of both Tregs and MDSC\(^\text{[50-52]}\). Recently, two studies have interrogated the simplified view of the immune cells’ roles in the context of brain tumors and the M1/M2 dichotomy\(^\text{[53,54]}\). They found that the immune landscape of brain tumors is much more
complicated and multifaceted than previously envisioned. The TME of each brain malignancy dictates the type of immune cells that will predominate. While glioma TMEs are enriched with microglia-derived TAMs, brain metastases originating from extracranial tumors are dominated by neutrophils and tumor infiltrating leukocytes, specifically Tregs. In brain metastases, TAMs are mainly tissue-infiltrating MDMs.
and are phenotypically distinct from MDMs identified in gliomas\(^{51}\). Intriguingly, the transcriptomic signature of TAMs did not reflect the M1/M2 polarization status in all brain tumors tested, but rather a multifaceted phenotype of TAMs sculpted by the underlying tumor type\(^{53,54}\). Collectively, these studies uncover the disease-specific alterations of immune cells, explaining the discrepancy in clinical outcomes of immunotherapy in patients with brain tumors.

Brain tumor cells not only secrete immunosuppressive factors, but they also express them on their surface. CD95 and CD70 are two cell surface markers associated with primary brain tumor stemness, aggressiveness, and progression through their inherent apoptotic and immunomodulatory effects on TAMs and infiltrating T-cells\(^{55,56}\). The rapid induction of indoleamine 2,3-dioxygenase (IDO) expression on brain tumor cells recruits Tregs and enhances tumor growth\(^{57,58}\). The hypoxic environment of brain tumors exhibits persistent activation of the signal transducer and activator of the transcription 3 pathway, an immunosuppressive pathway associated with poor survival\(^{59,60}\). Fibrinogen-like protein 2 expression in gliomas leads to the inhibition of immune cell differentiation while increasing the expression of M2 macrophages and programmed cell death protein-1 (PD-1)\(^{61,62}\). Increased expression of both PD-1 and cytotoxic T lymphocyte protein-4 (CTLA-4) on brain tumor cells affects tissue-resident T-cells (T\(_{RM}\)) and TAMs by limiting their phagocytic capacity\(^{63}\) and causing effector cell exhaustion\(^{64}\). The immunosuppressive nature of the brain TME is one of the challenges that needs to be addressed and targeted in immunotherapy.

**IMMUNOTHERAPEUTIC STRATEGIES FOR BRAIN CANCER**

**Checkpoint inhibition**

The concept of immune surveillance was proposed in the 1900s and defined as the host’s immunologic defense mechanisms to get rid of unhealthy cells. Immune checkpoints are molecules located on the surfaces of activated T-cells whose primary purpose is to inhibit uncontrolled inflammatory responses. The interaction of PD-1 and CTLA-4, the classical immune checkpoints, with their ligands signals T-cell inactivation and apoptosis, respectively. Therefore, checkpoint blockade can remove immune tolerance and restore activated T-cells [Figure 2A]\(^{65}\).

PD-1 and CTLA-4 are inhibitory immune receptors, or checkpoint inhibitors, predominately expressed on T-cells and functionally dysregulated in the TME\(^{66,67}\). PD-1 is an immune checkpoint inhibitor expressed on T-cells, myeloid cells, natural killer (NK) cells, and B lymphocytes\(^{68}\). The interaction of PD-1 with its ligands PD-L1 or PD-L2 present on antigen-presenting cells (APC) and tumor cells induces immune tolerance and suppression of T-cell activation\(^{64-70}\). Tumor cells utilize this mechanism to circumvent immune surveillance through the attenuation of T-cell responses\(^{69}\). CTLA-4, also known as CD152, is a member of the immunoglobulin superfamily and is the first coinhibitory molecule identified\(^{71}\). It is expressed on regulatory and activated T-cells but not on naïve T-cells\(^{72,73}\). Once CTLA4 interacts with its ligands CD80/CD86 on the surface of APCs, it inhibits costimulatory cell signaling pathways and decreases T-cell activation and responsiveness\(^{74}\).

A recent study shows that PD-1 expression in glioma patients’ tumor-infiltrating lymphocytes is a marker of T-cell exhaustion\(^{74}\). High expression of PD-1 and its ligands has been associated with lower prognosis in gliomas\(^{75,76}\) and various pediatric brain tumors (e.g., ependymoma and high-grade glioma)\(^{77}\). Similarly, gliomas with higher CTLA-4 expression exhibited more immune cell infiltration and worse overall survival (OS)\(^{74}\). Therefore, targeting immune checkpoint molecules offers an effective T-cell based immunotherapeutic approach for brain cancer treatment. The therapeutic efficacy of blocking the interaction of PD-1 and its ligand PD-L1, alone or in combination with CTLA-4 inhibitors, has been demonstrated in melanoma\(^{23,79}\), non-small cell lung cancer\(^{24,80}\), and renal cell carcinoma\(^{61}\). The success of checkpoint inhibitors in different cancers, particularly in untreated brain metastases\(^{42}\), motivated efforts to investigate their potential in the improvement of brain cancer outcomes.
Figure 2. Immunotherapeutic strategies for treatment of brain cancers. A: checkpoint blockade with monoclonal antibodies against PD-1 and CTLA-4 can block the interaction of these receptors with their ligands expressed on tumor cells leading to sustained T-cell activation and anti-tumor responses; B: vaccination therapy depends on dendritic cell antigen presentation of peptides or antigens derived from tumor lysates. In peptide vaccine therapy, peptides can be antigens encoded by mutant genes and thus be expressed only on tumor cells. These neoantigens are called TSA. Other peptides can be antigens derived from the modulated expression of normal peptides and are termed TAA. In cell-based vaccination, dendritic cells are expanded and activated 
\textit{ex vivo} with patient-tumor lysates prior to administration. Both vaccine modalities aim to stimulate anti-tumor humoral and cellular immune responses; C: in CAR T-cell therapy, autologous T-cells are isolated and transfected with CAR construct, and transferred back into patients. These T-cells can recognize tumor-associated antigens obviating the need for MHC-dependent antigen presentation; D: oncolytic virus therapy allows the preferential replication of the virus in tumor cells causing tumor cell lysis and release of antigens that can induce an immune response. This figure contains images from Servier Medical Art. CAR: chimeric antigen receptor; CD: cluster of differentiation; CTLA-4: cytotoxic T-lymphocyte-associated protein-4; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; IL-13Rα2: interleukin-13 receptor alpha 2; MHC: major histocompatibility complex; PD-1: programmed cell death-1; PD-L1: programmed death-ligand 1; TAA: tumor-associated antigens; TCR: T-cell receptor; TSA: tumor-specific antigen

The mounting interest in checkpoint inhibitors for brain cancer treatment has encouraged a series of clinical trials. Table 1 lists select completed clinical trials of PD-1 inhibitors in brain tumors. No completed trials were documented using CTLA-4 inhibitors as a monotherapy in brain cancers. The PD-1 inhibitor pembrolizumab is well-tolerated in refractory high-grade glioma patients, with a low response rate and increased progression-free survival (PFS) even in combination with bevacizumab \[^{83}\]. Bevacizumab is a VEGF-A inhibitor and is the only monoclonal antibody approved for use in recurrent human glioblastoma. However, a retrospective analysis reported that nivolumab (anti-PD-1) monotherapy did not afford a significant improvement in survival when administered as salvage therapy in recurrent glioblastoma progressing on bevacizumab \[^{84}\].

While clinical benefit is not always evident following monotherapeutic PD-1 blockade with nivolumab in resectable glioblastoma (NCT02550249), favorable changes are detected in the TME in terms of immune cell infiltration \[^{85}\]. The KEYNOTE-028 clinical trial reported relative tolerability of pembrolizumab monotherapy in a cohort of recurrent glioblastoma patients, with a median OS exceeding that afforded by conventional treatments \[^{86}\]. The significant extension of overall and PFS in recurrent glioblastoma patients treated with pembrolizumab as adjuvant or neoadjuvant therapy was associated with improvements in antitumor immunity, particularly with enhanced clonal expansion of T-cells \[^{27}\].
Few immunotherapeutic agents have reached advanced clinical stages in brain cancer patients. To date, no phase 3 clinical trials have been completed. Only one active trial is investigating the efficacy of PD-1 monotherapeutic blockade in comparison with VEGF-A inhibition in patients with recurrent glioblastoma (NCT02017717). While OS was comparable in both approaches, preliminary data showed that treatment with a PD-1 inhibitor ensured more durable responses than those with VEGF-A blockade [29]. The majority of clinical investigations examining the efficacy of checkpoint inhibitors are either ongoing or recruiting patients. Two phase 2 clinical trials studying the efficacy of nivolumab in selected rare CNS cancers and high-grade mutated gliomas (NCT03173950; NCT03925246) are currently recruiting patients. Other immune inhibitors, such as ipilimumab, pembrolizumab, and bevacizumab are also set to be evaluated.
in adult glioma patients at different disease stages (NCT02852655; NCT03425292). Pre-clinical studies support the therapeutic relevance of targeting IDO, a clinically relevant marker of poor survival which enhances Tregs-mediated immunosuppression in brain tumors\(^{[57,58]}\). In pediatric populations, the efficacy of indoximod, an anti-IDO agent, is being investigated in combination with chemotherapy and/or radiation for children with progressive brain tumors or newly diagnosed diffuse intrinsic pontine glioma in a phase 2 trial (NCT04049669). Other clinical efforts remain in earlier phase 1 stages and mainly examine the efficacy of PD-1 blockade in younger brain cancer cohorts (NCT02359565; NCT02359565).

**Vaccines**

Therapeutic immunization against brain tumors aims to stimulate patient antitumor immunity through the recognition of tumor-associated antigens by T-cells [Figure 2B]. This is expected to elicit an immune response, which eventually leads to the eradication of cancer cells. The development of cancer vaccines differs from the conventional prophylactic preventative vaccines against infections at multiple levels. The immunocompromised state of the patients, the poor immunogenicity of self-antigens, and the capability of tumor cells to evade and suppress the immune system are challenges that cancer vaccination needs to overcome. The immunization of patients is usually achieved with either tumor-specific peptide(s) or autologous/allogeneic \textit{ex vivo}-modified cells primed with patient’s own tumor antigens. So, cancer vaccines include peptide vaccines and cell-based vaccines. In peptide vaccination, tumor specific antigens (e.g., EGFRvIII, heat shock proteins) are injected into the patient to elicit an immune response. Cell-based vaccines employ the injection of \textit{ex vivo}-modified cells (tumor cells, dendritic cells) to induce immunogenic tumor cell destruction.

Early studies have reported the potential immunological and clinical benefit as well as the relative tolerability of integrating vaccine therapy into malignant glioma treatment regimens [Table 1]\(^{[87,88]}\). The identification of the tumor-associated antigen, epidermal growth factor receptor variant III (EGFRvIII), led to the development of the EGFRvIII-specific peptide (PEPvIII) vaccine. PEPvIII induced a significant increase in humoral response against EGFRvIII in glioblastoma patients\(^{[89]}\). An EGFRvIII-targeted vaccine also seems promising in patients with glioblastoma subsets expressing this receptor as it has increased OS when compared to unvaccinated matched controls\(^{[90]}\). Despite the possible benefits of EGFRvIII-targeting vaccines, the heterogeneity of brain tumors and the immunological escape at recurrence may restrict the efficacy of this therapeutic approach claiming further clinical investigations\(^{[90]}\).

Heat shock proteins (HSPs) are a family of stress-related chaperone molecules that possess the capacity to bind to tumor-associated antigens and induce targeted antitumor immune responses\(^{[91]}\). The HSP vaccine is made up of a complex of HSP and autologous tumor antigen. The heat shock protein peptide complex-96 (HSPPC-96) is the HSP vaccine mainly used in brain cancer treatment. Vaccination using this peptide in newly diagnosed glioblastoma was proven safe and effective in early clinical findings with more than two-fold increase in tumor-specific immune response and a significant increase in OS\(^{[92]}\). Vaccinated patients survived more than 40 months, compared to an average of 14.6 months among their unvaccinated low tumor-specific immune response counterparts\(^{[92]}\). HSPPC-96 vaccination after gross total resection of recurrent glioblastoma also showed tolerability in a phase 2 clinical trial. The majority of patients (90.2%) survived 6 months after treatment, and 29.3% were alive after 1 year\(^{[93]}\).

Cell-based vaccines made from autologous or allogeneic \textit{ex vivo}-modified cells have also attracted their share of clinical interest. The cells can be dendritic cells, tumor cells, or other immune cells. The most common approach comprises blood-isolated dendritic cells, which are pulsed with tumor lysates, activated, and reinjected into patients as vaccines. Phase 1 studies have demonstrated the feasibility, safety, and bioactivity of tumor lysate-pulsed dendritic cells for the treatment of malignant gliomas\(^{[94,95]}\). Subsequently, multiple phase 2 studies have been completed but not published in brain cancer patients.
A dendritic cell-based vaccine was also used in a phase 1/2 trial to target cancer stem cells and was found to cause a 2.9-fold increase in PFS in glioblastoma patients\[^{[96]}\]. Vaccination with autologous tumor lysate-loaded DCs favored the survival of glioblastoma patients treated with radiotherapy and chemotheraphy and induced tumor-specific responses\[^{[97]}\]. However, the variability in vaccine-induced immunogenicity shows that much remains to be learned about the optimal preparation, contents, and dose of dendritic cell-based vaccines in brain cancer patients\[^{[98]}\]. Another cell-based vaccine, ICT-107, was generated using autologous DCs pulsed with synthetic peptides targeting antigens (e.g., MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Ra2) associated with either glioblastoma tumor cells or stem cells. ICT-107 was used for the therapeutic vaccination of adult patients with newly diagnosed glioblastoma in a phase 2b clinical trial. Patients treated with ICT-107 showed a significant improvement in PFS and maintenance of quality of life, particularly those exhibiting HLA-A2 primary tumor antigen expression\[^{[99]}\].

**Cell-based immunotherapy**

Adoptive T-cell therapy (ACT) is emerging as a novel and promising immunotherapeutic strategy against brain tumors. The most successful ACT approach involves the transfection of a chimeric antigen receptor (CAR) construct directed at various tumor antigens into autologous T-lymphocytes [Figure 2C]\[^{[100]}\]. Independent of MHC co-stimulation, the engineered T-cells can home in to the tumor cells once they are infused in the patient. This alleviates the immunosuppressive TME characteristic of brain tumors and induces the destruction of malignant T-cells. The leading CAR candidates in brain cancer include interleukin-13 receptor alpha 2 (IL-13Ra2), EGFRvIII, and human epidermal growth factor receptor 2 (HER2)\[^{[101]}\].

IL13Ra2 is the first CAR target clinically developed and optimized for adoptive cell therapy in brain cancers. Expressed on glioma stem-like cells (GSC) and differentiated cancer cells, IL13Ra2 proves to be an effective immunotherapeutic target and renders both cell populations susceptible to cytotoxic activity of the first generation IL13Ra2-CAR T-cells, termed IL13-zetakine. Engineered IL13-zetakine T-cells were shown to have abolished GSC and differentiated tumor cells both in vitro and in vivo\[^{[102]}\]. A preclinical study in a murine model demonstrated the ability of IL13Ra2-CAR T-cells to efficiently kill glioma cells and to shift the glioblastoma TME to a pro-inflammatory landscape\[^{[103]}\]. In a clinical setting, a pilot study of three patients with refractory glioblastoma was conducted and showed an increase in tumor necrosis following the intracranial administration of IL13Ra2-specific CAR-T-cells\[^{[104]}\]. To improve the antitumor potential of this adoptive cell therapy, a patient suffering from recurrent multifocal glioblastoma received an IL13Ra2-CAR T-cell treatment and experienced dramatic regression of his tumors\[^{[105]}\]. Donor-derived allogenic CAR CD8+ T-cells can also be induced to express IL13 zetakine/HyTk CAR and used to treat refractory high-grade glioma in combination with IL-2 (NCT01082926).

As a tumor-specific antigen, EGFRvIII seems to be a promising CAR target for brain tumors, and has attracted clinical attention. The first phase 1 trial (NCT02209376) of CAR T-cells directed against EGFRvIII showed trafficking of engineered T-cells to the tumor site, T-cell expansion, and downregulation of EGFRvIII expression in tumors suggesting antigen-directed cytoltyic activity\[^{[106]}\]. However, another recent phase 1 pilot study (NCT01454596) using anti-EGFRvIII CAR-T-cell therapy did not show clinical significance in patients with recurrent glioblastoma. The transduced T-cells were administered in a dose-escalation pattern with intravenous IL-2 support. They caused severe pulmonary toxicity in two patients and the death of another patient upon administration of T-cells at the highest dose\[^{[107]}\]. These studies highlight the barriers associated with EGFRvIII-CAR T-cell therapy in the treatment of brain tumors. Since no significant antitumor responses were shown, these clinical trials mandate the need to better understand the challenges associated with adoptive cell therapy; in particular, the heterogeneity of EGFRvIII expression and the immunosuppressive environment of brain tumors.
HER2-CAR T-cell immunotherapy remains in the early stages of brain cancer treatment. Safety became an issue while targeting HER2 after the first patient receiving HER2-CART-cell immunotherapy died. Recently, a phase 1 trial (NCT01109095) using bispecific CAR-T-cells aimed to improve the persistence and safety of HER2-CAR T-cells. The engineered T-cells expressed CARs specific for cytomegalovirus and HER-2. This trial demonstrated a clinical benefit in 38% of patients with progressive glioblastoma, and the therapy was well tolerated.\[108\]

Although targeting the aforementioned tumor-associated antigens (i.e., IL13Ra2, EGFRvIII, and HER2) has shown clinical benefit in patients with brain tumors, tumor heterogeneity and subsequent resistance against CAR T-cells underscore the need to discover a new repertoire of targeted antigens. In this context, preclinical investigations for CAR therapy in brain cancers have been initiated and a set of new antigens [e.g., B7-H3, CD133, CSPG4, ephrin A2 (EphA2), and GD2] are being intensively explored. Some of these antigens have already found their way to clinical trials but the results are not published yet, such as EphA2 (NCT02575261), GD2 (NCT03252171), and B7–H3 (NCT04185038).\[109\]

Although CAR-T-cell immunotherapies have received FDA approval in certain settings, they remain associated with significantly high costs, off-target effects on healthy tissues, as well as other toxicities such as cytokine release syndrome. In addition, failures of many immunotherapeutic approaches for the treatment of glioblastoma pleaded the need for alternative strategies. One promising approach includes NK cells, the lymphocytes of innate immunity, which are capable of eliminating malignant T-cells and coordinating the crosstalk between DCs and T-cells without the need for antigen presentation. The clinical effectiveness of NK-based immunotherapy lies in the ability of NK cells to leverage antitumor immunity and DC-mediated T-cell activation through identification and elimination of cells that lack self-MHC class I molecules. This favors the utility of allogeneic NK cells from healthy donors as they will not recognize tumor cells as self and will not induce graft-vs-host-disease. Engineering NK cells instead of T-cells is therefore expected to have higher clinical efficacy and safety (reviewed extensively in Burger et al.). So, ongoing efforts are directed to enhance NK-cell therapeutics ranging from blockade of their inhibitory receptor pathways to specifically targeting tumor cells using bispecific antibodies or CARs. Clinical studies remain in their earlier stages in glioblastoma, with ErbB2 (HER2)-specific CAR-NK cells currently under investigation in the CAR2BRAIN phase 1 study (NCT03383978).

CAR-T and NK cell therapy is not the only weapon in the arsenal of cellular immunotherapy. Other methods include the generation of intracavitary alloreactive cytotoxic T lymphocytes sensitized to MHC and their administration with interleukin-2 (IL-2). This strategy proved to be well-tolerated in recurrent malignant glioma patients. Intralesional exposure of resectable glioblastoma tumors to autologous lymphokine-activated killer cells is another safe cell-based immunotherapy with promising results in terms of patient survival. Systemic adoptive cell therapy has also been reported in clinical trials and involves the administration of ex-vivo activated T or NK cells to treat tumors. A phase 2 trial examined the inoculation of irradiated tumor cells in malignant glioma patients, followed by isolation and transfer of ex-vivo expanded T-cells. The clinical results were not conclusive and warranted further investigation. Recent efforts have examined the safety, tolerability, and preliminary efficacy of autologous NK cell-based immunotherapy both in adult (NCT01588769) and pediatric (NCT01875601) brain cancer patients, but results are not yet published. Cellular and adoptive immunotherapies are also being investigated in a phase 2 trial in solid tumor patients receiving NK cells from haploidentical donors (NCT02100891). Another phase 1 study is also set to determine the feasibility and safety of administering gene-modified drug-resistant γδ T-cells. These cells will be generated from newly diagnosed glioblastoma patients’ own lymphocytes and will be administered with temozolomide (TMZ) chemotherapy (NCT04165941).
Oncolytic viral therapy

Powered by advancements in DNA recombinant technology, oncolytic virotherapy has emerged as a promising cancer therapeutic candidate. During infection, viruses use host replication machinery to amplify their genetic code and expand in numbers. This results in the inevitable lysis of the host T-cell and the spreading of the viral progeny [Figure 2D]. In virotherapy, viruses are engineered to selectively infect cancer cells and to minimize immunosuppression of viral agents\textsuperscript{[117]}. Oncolytic viruses are seen as a potential therapeutic approach in the notoriously challenging field of brain tumor treatment. Completed clinical trials have mainly utilized one of the two genetically modified viruses, adenovirus and herpes simplex virus (HSV), to target brain cancer cells [Table 1]. Other virotherapeutic agents with anti-glioma effects are currently under investigation in phase 1/2 clinical trials including reovirus, poliovirus, parvovirus, measles, and Newcastle disease virus\textsuperscript{[118]}.

DNX-2401 (Delta-24-RGD; tasadenoturev) is an oncolytic adenovirus designed to be replication-competent and glioma-selective. The oncolytic efficacy of DNX-2401 has been proven in both adult and pediatric glioma models along with its capacity to induce antitumor immune responses\textsuperscript{[119]}. In a phase 1 clinical study, intratumoral DNX-2401 demonstrated satisfactory clinical activity, tolerability, and safety in recurrent high-grade glioma patients\textsuperscript{[120]}. These promising results fueled phase 2 trials of this oncolytic virus in either glioblastoma alone (NCT01582516) or in combination with a PD-1 inhibitor (CAPTIVE/KEYNOTE-192; NCT02798406), and a phase 1 study in newly diagnosed pediatric glioma (NCT03178032). In another phase 1 trial, neural stem cells loaded with a conditionally replicative oncolytic adenoviral vector (CRAd), NSC-CRAd-Spk7, were injected in patients with malignant gliomas. Following viral infection with NSC-CRAd-Spk7, the tumor-specific survivin promoter induces the lysis of malignant T-cells. While the clinical investigations of this virotherapy are completed, the therapeutic value of this approach is not yet reported (NCT03072134).

Oncolytic HSV is the first recombinant virus developed and armed with various therapeutic genes to be used in the treatment of different cancers\textsuperscript{[121]}. G207 is a conditionally replicating derivative of HSV widely used in brain cancer therapy. Inoculation of glial tumors with G207 induced radiographically and neuropathologically evident activity against tumor cells\textsuperscript{[122]}. More importantly, G207 viral infection seems to be durable without eliciting any HSV encephalitis, toxicity, or serious adverse events\textsuperscript{[122]}. The promising therapeutic activity of G207 has warranted investigations in pediatric cohorts prevalent with refractory cerebellar brain tumors (NCT03911388) as well as recurrent supratentorial brain tumors with or without a single radiation dose (NCT02457845). The results of these two studies are not published yet.

Other clinical efforts remain in their early stages and seem to predominately assess the safety and efficacy of other genetically engineered HSVs (NCT02062827; NCT03152318; NCT03657576) and a Polio/Rhinovirus recombinant (NCT01491893) in adult malignant recurrent brain tumors. Evidence from a published phase 1/2a trial reflect the safety, clinical efficiency, and immunostimulatory capacity of ParvOryx01, an H-1 parvovirus, when administered in recurrent glioblastoma patients\textsuperscript{[123]}. Pediatric gliomas and other primary brain tumors have not been excluded from the clinical investigations of oncolytic viruses. Viral strains under investigation include a Polio/Rhinovirus Recombinant (NCT03043391) and a Replication Competent Reovirus (Reolysin\textsuperscript{®}) (NCT02444546), which has reached phase 3 stage in the clinical course of treating head and neck cancers (NCT01166542).

Combination therapy

Single immunotherapeutic strategies have failed to result in effective clinical responses in patients with brain tumors. This is attributed to the multiple immune evasion mechanisms of brain cancers and their tumor heterogeneity. To surmount this issue, combinatorial immune-based approaches that can target multiple branches of the immune system have been suggested. Immune checkpoint inhibitors provide
brain cancer patients with ever fleeting improvements in OS when combined with other agents or therapies (e.g., radiotherapy or chemotherapy) [Table 2]. Administered with standard radiotherapy, the anti-PD-L1 agent Durvalumab prolonged survival up to 34.9 months in patients with newly diagnosed unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) glioblastoma\(^\text{[124]}\). Another PD-L1 inhibitor called avelumab did not exhibit satisfactory clinical activity in a phase 2 trial investigating its combination with a tyrosine kinase inhibitor in recurrent glioblastoma patients\(^\text{[125]}\). PD-1 blockade using pembrolizumab showed satisfactory tolerability in recurrent glioblastoma patients regardless of their treatment arm and demonstrated superior clinical efficiency when administered in combination with bevacizumab than when administered alone\(^\text{[126]}\). The preliminary results of a phase 1 clinical trial examining the efficacy of nivolumab (anti-PD-1) in combination with a dendritic cell vaccine prior to or after surgical resection of recurrent brain tumors, have recently been reported. The combination resulted in prolonged OS and PFS when administered before surgery, albeit with more reported adverse effects (NCT02529072). Another completed clinical trial (NCT02052648) evaluated the safety and tolerability of IDO inhibitor and TMZ combination with or without bevacizumab or radiation in patients with malignant brain tumors with no published results. Checkmate 498 is an active phase 3 clinical trial investigating whether the combination of nivolumab and radiotherapy provides an advantage to adult patients with newly diagnosed unmethylated MGMT glioblastoma in comparison with standard therapy of TMZ and radiotherapy (NCT02617589). The addition of nivolumab to standard TMZ plus radiation therapy is also under active investigation in a phase 3 study of newly diagnosed adult subjects with MGMT-methylated glioblastoma (NCT02667587). The combination of nivolumab with another checkpoint inhibitor known as anti-lymphocyte-activation gene 3 is planned in a phase 1 study (NCT02658981). Another recruiting phase 1 trial aims to evaluate the safety and tolerability of pembrolizumab and vorinostat (a histone deacetylase inhibitor) in combination with TMZ and radiotherapy in adult glioblastoma cohorts (NCT03426891). The combination of TMZ-based therapy with IDO immune checkpoint inhibition is currently under investigation in a phase 1 study to treat pediatric patients (NCT02502708).

The synergistic effects of cancer vaccines and other immunotherapeutic approaches or standard-of-care treatment have been reported in clinical trials [Table 3]. The integration of autologous dendritic cell-based vaccination with the standard glioblastoma treatment regimen of surgical resection, radiotherapy, and chemotherapy was evaluated in a phase 2 study. This combination proved to be feasible, safe, and clinically beneficial\(^\text{[127]}\). In a large phase 3 clinical trial, the concomitant use of autologous tumor lysate-pulsed dendritic cell vaccine and standard chemoradiotherapy with TMZ in newly diagnosed glioblastoma patients demonstrated feasibility, safety, and survival-improving potential\(^\text{[32]}\). The results of other clinical trials investigating the efficacy of combining first-in-line brain cancer treatment with DCs loaded with

<table>
<thead>
<tr>
<th>Drug name or therapy</th>
<th>Intervention or therapeutic target</th>
<th>Patient population</th>
<th>Study phase</th>
<th>Tumor type</th>
<th>Median OS (months)</th>
<th>Median PFS (months)</th>
<th>Study identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab ± bevacizumab</td>
<td>Anti-PD-1 ± anti-VEGF-A</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Recurrent glioblastoma</td>
<td>+bevacizumab: 8.8 -bevacizumab: 10.3</td>
<td>N/A</td>
<td>NCT02337491</td>
</tr>
<tr>
<td>Indoximod + TMZ with or without bevacizumab or radiation</td>
<td>Anti-IDO + chemotherapy with or without anti-VEGF-A or radiation</td>
<td>Child, Adult, Older Adult</td>
<td>1/2</td>
<td>TMZ-Refractory Primary Malignant Brain Tumors</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT02052648</td>
</tr>
<tr>
<td>Durvalumab + radiotherapy</td>
<td>Anti-PD-L1 + Radiotherapy</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Newly diagnosed unmethylated MGMT glioblastoma</td>
<td>15.1</td>
<td>N/A</td>
<td>NCT02336165</td>
</tr>
<tr>
<td>Avelumab + axitinib</td>
<td>Anti-PD-L1 + tyrosine kinase inhibitor</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Recurrent glioblastoma</td>
<td>6.5</td>
<td>N/A</td>
<td>NCT03291314</td>
</tr>
</tbody>
</table>

MGMT: O(6)-Methylguanine-DNA methyltransferase; N/A: not available; OS: overall survival; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1; PFS: progression-free survival; TMZ: temozolomide; VEGF-A: vascular endothelial growth factor A
Table 3. Select completed clinical trials of cancer vaccines in combination with other immunotherapeutic or standard-of-care approaches

<table>
<thead>
<tr>
<th>Vaccine/therapy name</th>
<th>Therapeutic target</th>
<th>Patient population</th>
<th>Study phase</th>
<th>Tumor type</th>
<th>Median OS (months)</th>
<th>Median PFS (months)</th>
<th>Study identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuncell-LC + TMZ</td>
<td>Autologous CIK cells + chemotherapy</td>
<td>Adult, Older adult</td>
<td>3</td>
<td>Newly diagnosed glioblastoma</td>
<td>22.5</td>
<td>8.1</td>
<td>NCT00807027</td>
</tr>
<tr>
<td></td>
<td>Autologous whole-tumor cell vaccines + GM-CSF + adoptive transfer of T lymphocytes</td>
<td>Adult, Older adult</td>
<td>2</td>
<td>Primary or Recurrent Astrocytoma or Oligodendroglioma</td>
<td>12</td>
<td>N/A</td>
<td>NCT00004024</td>
</tr>
<tr>
<td></td>
<td>Autologous tumor cell vaccine + GM-CSF + ex vivo activated T-cell adoptive therapy</td>
<td>Adult, Older adult</td>
<td>2</td>
<td>Glioblastoma</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT00003185</td>
</tr>
<tr>
<td>TVAX</td>
<td>TVI-Brain-1 (autologous whole-tumor cell vaccine) + adoptive transfer of T lymphocytes</td>
<td>Adult, Older adult</td>
<td>1/2</td>
<td>Recurrent grade IV glioma</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT01081223</td>
</tr>
<tr>
<td>TVAX</td>
<td>TVI-Brain-1 (autologous whole-tumor vaccine) + GM-CSF + adoptive transfer of anti-CD3-activated lymphocytes</td>
<td>Adult, Older adult</td>
<td>2</td>
<td>Glioblastoma</td>
<td>12</td>
<td>N/A</td>
<td>NCT00905060</td>
</tr>
<tr>
<td>Rindopepimut (CDX-110) + bevacizumab</td>
<td>Anti-EGFRvIII vaccine + anti-VEGF-A</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Newly diagnosed EGFRvIII-expressing glioblastoma</td>
<td>23.6</td>
<td>15.2</td>
<td>NCT00643097</td>
</tr>
<tr>
<td>Rindopepimut (CDX-110) + sargramostim + TMZ</td>
<td>Anti-EGFRvIII vaccine + GM-CSF + chemotherapy</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Relapsed EGFRvIII-positive glioblastoma</td>
<td>N/A</td>
<td>3.7</td>
<td>NCT01498328</td>
</tr>
<tr>
<td>Rindopepimut (CDX-110) + sargramostim</td>
<td>Autoologous tumor-derived heat shock protein peptide-complex (HSPPC-96) + chemotherapy</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Newly diagnosed glioblastoma</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT00905060</td>
</tr>
<tr>
<td>PEP-III-KLH</td>
<td>Anti-EGFRvIII vaccine + GM-CSF</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Newly diagnosed glioblastoma</td>
<td>23.6</td>
<td>15.2</td>
<td>NCT00643097</td>
</tr>
<tr>
<td>Autologous DCs pulsed with tumor lysate + standard therapy</td>
<td>Autoologous DCs pulsed with tumor lysate + standard therapy</td>
<td>Adult, Older Adult</td>
<td>2</td>
<td>Glioblastoma</td>
<td>23.4</td>
<td>12.7</td>
<td>NCT01006044</td>
</tr>
<tr>
<td>Trivax + TMZ + Surgery + Radiotherapy</td>
<td>Tumour-lysate Charged DCs + Chemotherapy + Surgery + Radiotherapy</td>
<td>Child, Adult, Older Adult</td>
<td>2</td>
<td>High-grade glioma</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT01213407</td>
</tr>
<tr>
<td>IMA950 + Hiltonol + TMZ</td>
<td>Multi tumour-associated peptides (TUMAPs) vaccine + poly-ICLC + chemotherapy</td>
<td>Adult, Older Adult</td>
<td>1/2</td>
<td>Glioblastoma</td>
<td>19</td>
<td>N/A</td>
<td>NCT01920191</td>
</tr>
<tr>
<td>SL-701 + poly-ICLC</td>
<td>Synthetic peptides + poly-ICLC</td>
<td>Adult, Older Adult</td>
<td>1/2</td>
<td>Recurrent or refractory brain tumor</td>
<td>N/A</td>
<td>N/A</td>
<td>NCT00014573</td>
</tr>
</tbody>
</table>

CIK: cytokine-induced killer; CNS: central nervous system; DC: dendritic cell; EGFRvIII: epidermal growth factor receptor variant III; GM-CSF: granulocyte-macrophage colony stimulating factor; N/A: not available; OS: overall survival; PFS: progression-free survival; poly-ICLC: polyinosinic-polycytidylic acid with poly-L-lysine and carboxymethylcellulose; TMZ: temozolomide
autologous tumor lysates are not published yet (NCT01213407; NCT02496520). Another phase 3 study evaluated the addition of autologous cytokine-induced killer cells to radiotherapy-TMZ in newly diagnosed glioblastoma patients. The trial significantly improved PFS, but not OS[128].

Multiple phase 2 trials have assessed the efficacy of adoptive cell therapy after the use of autologous whole-tumor vaccines, such as TVAX, in combination with granulocyte-macrophage colony-stimulating factor (NCT00004024; NCT01081223; NCT01290692; NCT00014573), but the final results are unavailable to date. Results of the combination of chemotherapy with autologous tumor-derived HSPC-96 are also expected from a completed phase 2 trial in adult patients with newly diagnosed glioblastoma (NCT00905060). Vaccines integrating multiple tumor-associated peptides have been reported and include IMA950 multipeptide which in combination with adjuvant poly-ICLC ensured almost 20 months median OS and induced both CD8 and CD4 T-cell responses. This was reported in newly diagnosed glioblastoma and grade III astrocytoma patients treated with radiochemotherapy[129]. SL-701 is another vaccine under investigation in a completed but unpublished phase 1/2 study examining the effect of administering survivin, IL-13Rα2; and EphA2 in combination with poly-ICLC in recurrent glioblastoma patients (NCT02078648). Poly-ICLC has also been administered in combination with Type-1 αDCs (αDC1) loaded with synthetic peptides associated with brain tumors, such as glioma-associated antigen epitopes, ensuring up to 32.88 median OS with relative tolerability (NCT00766753).

The combination of autologous whole-cell tumor vaccines and adoptive T-cell therapy seems promising for the treatment of grade IV glioma and primary or recurrent astrocytoma or oligodendroglioma (NCT01081223; NCT00004024), while its effect on glioblastoma in a phase 2 clinical trial setting remains unpublished (NCT00003185). In fact, adoptive transfer of in vitro activated T lymphocytes after vaccination induced a radiologically-detectable tumor response and prolonged survival in patients with recurrent gliomas[130].

Treatment of glioblastoma patients with intensified doses of chemotherapy (TMZ) and EGFRvIII-targeted vaccines potentiated vaccine-induced immune responses, eliminated EGFRvIII-expressing tumor cells and extended PFS and OS[131]. EGFRvIII-targeted vaccination using rindopepimut in a phase 2 trial confirmed promising clinical results for glioblastoma patients once rindopepimut was combined with chemotherapy (TMZ)[132]. However, the concurrent administration of rindopepimut vaccine and TMZ in patients with glioblastoma failed to prolong the survival in a phase 3 clinical trial[133]. Most recently, published results from a phase 2 study support the combination of rindopepimut and bevacizumab which confer survival advantage as well as effective antitumor responses[134]. Collectively, these results warrant further investigations into combinatorial approaches that provide the most efficient immunotherapeutic strategy in patients with brain tumors.

CONCLUSIONS AND FUTURE PERSPECTIVES

Clinical investigations into immunotherapeutic strategies for the treatment of brain cancer lag behind similar efforts in other cancer types due to the heterogeneity and low mutational burden of brain tumors, and the immunosuppressive and evolving nature of the tumor microenvironment. Other challenges involve T-cell sequestration in bone marrow[135] and disease-specific immunological niches[53,54]. Intracranial associated T-cell sequestration is indicative of T-cell dysfunction that contributes to tumor escape from immune surveillance[135]. The diversity of immune landscapes sculpted by different brain tumors highlights the need for better understanding of the immune cell phenotypes and functional states in each tumor type to facilitate the design of targeted immunotherapeutic approaches. Despite these hurdles, harnessing the immune system to restore antitumor immunity and to alleviate brain tumor-induced immunosuppression remains a window-of-hope for brain tumor patients. In a cancer population with a traditionally dismal prognosis, immunotherapeutic agents alone or in combination with current standard-of-care can afford a
much-needed improvement in patient survival while delaying disease progression. The preliminary efficacy and tolerability of immunotherapies is evident and warrants further investigation to optimally integrate them in brain cancer management. Significant questions remain unanswered. How does the brain cancer cell affect each distinct type of immune cells starting from T-cell sequestration in bone marrow to their specific enrichment based on tumor type? Do treatment strategies influence the cross-talk between the brain tumor cells and immune cells? What about ECM as an immunotherapeutic target? Would investment in innate immunity like NK cells or even neutrophils be promising? Collectively, in-depth knowledge of the immunological signatures and their interaction with brain tumor cells is needed to develop novel immunotherapeutic agents that can be the future first-in-line curative treatments for brain tumors.

DECLARATIONS

Acknowledgments
The authors thank Nicholas D. Yaeger, Junji Chen, and Zachary A. Blashinsky for the initial scientific literature search and summary.

Authors’ contributions
Designed the outline, wrote the paper, and drew figures: Khamis ZI
Wrote the paper, drew figures, and prepared tables: Al-Akkary N
Assisted with literature search and summary, manuscript revision, and figure preparation: Hua T, Draughon SA
Revised the manuscript: Li Y
Conceived the idea, directed this work, designed the outline, and revised the manuscript: Sang QXA
Obtained the funding: Khamis ZI, Li Y, Sang QXA

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was in part supported by Florida Department of Health (FDOH) Live Like Bella award (9LA01) (to Sang QXA and Li Y). http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/bellafoa.html. The authors are also funded in part by the Florida State University. This work is also funded by an Endowed Chair Professorship in Cancer Research from anonymous donors (to Sang QXA), and a Lebanese grant (to Khamis ZI). The funding agencies and funders did not play any role in the study design, collection, analysis and interpretation of data, and writing of the manuscript.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.
REFERENCES


59. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, et al. FGL2 as a multimodality regulator of tumor-mediated immune suppression and
91. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science


